Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-K/A
2021 FY
Annual report (amended)
31 Oct 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Departure of Directors or Certain Officers
11 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
27 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Feb 24
8-K
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
6 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Regulation FD Disclosure
13 Sep 23
8-K
Regulation FD Disclosure
9 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
424B5
Prospectus supplement for primary offering
15 Jun 23
FWP
Free writing prospectus
15 Jun 23
S-8
Registration of securities for employees
9 Aug 22
424B5
Prospectus supplement for primary offering
16 May 22
424B5
Prospectus supplement for primary offering
27 Apr 22
424B5
Prospectus supplement for primary offering
30 Jun 21
424B5
Prospectus supplement for primary offering
28 Jun 21
S-3ASR
Automatic shelf registration
4 May 21
Proxies
DEFA14A
Additional proxy soliciting materials
10 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
31 May 22
DEFA14A
Additional proxy soliciting materials
18 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
Other
UPLOAD
Letter from SEC
29 Jun 22
CORRESP
Correspondence with SEC
22 Jun 22
UPLOAD
Letter from SEC
9 Jun 22
CORRESP
Correspondence with SEC
26 May 22
UPLOAD
Letter from SEC
12 May 22
EFFECT
Notice of effectiveness
30 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
CORRESP
Correspondence with SEC
27 Jul 20
UPLOAD
Letter from SEC
14 Jul 20
SEC STAFF
SEC staff action: Order
6 Apr 20
Ownership
3
Vincent Vultaggio
11 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
4
Melissa B, Epperly
12 Feb 24
4
Cam Gallagher
12 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24